What Clinical Strategies Are Applied for Botulinum Toxin Injection in the Oromandibular Region?

TY - CHAP

T1 - What Clinical Strategies Are Applied for Botulinum Toxin Injection in the Oromandibular Region?

AU - Bakke, Merete

AU - Dalager, Torben

AU - Møller, Eigild

PY - 2016

Y1 - 2016

N2 - Botulinum neurotoxin (BoNT) inhibits the release of acetylcholine from cholinergic nerve terminals in muscles or salivary glands. With reduced activation, the muscle activity or secretion decreases. Indications for medical, non‐cosmetic use of BoNT in the orofacial area include among others oromandibular dystonia, painful masseter hypertrophy, Frey's syndrome, and severe drooling. The chapter covers anamnestic characteristics of these conditions as well as clinical, electromyographic (EMG) and laboratory findings, treatment methods with guided injections, and outcome from systematic treatment controls and follow‐up examinations.

AB - Botulinum neurotoxin (BoNT) inhibits the release of acetylcholine from cholinergic nerve terminals in muscles or salivary glands. With reduced activation, the muscle activity or secretion decreases. Indications for medical, non‐cosmetic use of BoNT in the orofacial area include among others oromandibular dystonia, painful masseter hypertrophy, Frey's syndrome, and severe drooling. The chapter covers anamnestic characteristics of these conditions as well as clinical, electromyographic (EMG) and laboratory findings, treatment methods with guided injections, and outcome from systematic treatment controls and follow‐up examinations.

U2 - 10.5772/64271

DO - 10.5772/64271

M3 - Book chapter

SN - 978-953-51-2852-6

SP - 79

EP - 95

BT - Botulinum Toxin Therapy Manual for Dystonia and Spasticity

A2 - Rosales, R

A2 - Dressler, D

PB - InTechOpen

CY - Rijeka

ER -